Which peptides is the FDA advisory committee reviewing in July 2026?

According to the FDA meeting notice, the Pharmacy Compounding Advisory Committee is scheduled to review BPC-157, KPV, TB-500 (thymosin beta-4 fragment), and MOTS-C on July 23, 2026, and DSIP (delta sleep-inducing peptide), Semax, and Epitalon on July 24, 2026.

What is the difference between Category 1 and Category 2 for compounding?

In the FDA's framework for bulk drug substances used in compounding, Category 1 substances are those under evaluation for which the FDA generally applies enforcement discretion while review continues, whereas Category 2 substances are those the agency has identified as potentially presenting significant safety risks. Placement can change as the FDA reviews new evidence.

Does regulatory review mean these peptides are approved or unapproved drugs?

No. Regulatory review of compounding eligibility is a separate question from drug approval. None of these peptides is being marketed by Ethos Bio as an approved drug. Ethos Bio supplies them as research-use-only reference materials for laboratory study, not for human or veterinary use, diagnosis, or treatment.

Research Library · Regulatory

Peptide Regulatory Status: 2026

Q: What is happening with peptide regulation in 2026?

In 2026 the U.S. Food and Drug Administration is actively re-evaluating the regulatory status of several peptides considered for pharmacy compounding. The FDA's Pharmacy Compounding Advisory Committee is scheduled to meet on July 23-24, 2026 to review evidence on a set of peptides for 503A compounding eligibility. Separately, Ethos Bio supplies these compounds strictly for laboratory research use only, not for compounding or human use.

Q: How does this affect Ethos Bio customers?

Ethos Bio sells all compounds strictly for laboratory research use only. Research-use-only supply is a distinct channel from pharmacy compounding for patient use. Ethos Bio monitors the regulatory landscape and maintains strict research-use-only framing, independent third-party testing, and documentation on every lot.

A plain-language tracker of the evolving U.S. regulatory landscape for research peptides — what the FDA is reviewing, what the terms mean, and where research-use-only supply fits. Updated as the picture changes.

Updated Jul 2026InformationalResearch Use Only

01The Short Version

Through 2026 the U.S. Food and Drug Administration has been actively re-evaluating how several peptides are treated under its pharmacy compounding framework. The FDA's Pharmacy Compounding Advisory Committee is scheduled to meet on July 23–24, 2026 to review evidence on a group of peptides for potential 503A compounding eligibility.

Important boundary: pharmacy compounding for patient use and research-use-only supply are two different channels. Ethos Bio supplies these compounds strictly for laboratory research — not for compounding, human use, or treatment. This page reports the regulatory picture; it is not compounding, dosing, or medical guidance.

02Peptides Under Advisory Review

Per the FDA meeting notice, the advisory committee is scheduled to review the following, several of which are studied widely in the research community:

Scheduled July 23, 2026

BPC-157 KPV TB-500 MOTS-C

Scheduled July 24, 2026

DSIP Semax Epitalon

Source: U.S. FDA, Pharmacy Compounding Advisory Committee meeting announcement (July 23–24, 2026); public docket FDA-2026-N-2979. Scheduling and agenda are set by the FDA and may change.

03What the Categories Mean

When a substance is proposed for use in compounding, the FDA sorts bulk drug substances into working categories while it evaluates them:

Category 1	Under evaluation; the FDA generally applies enforcement discretion while review continues.
Category 2	Identified as potentially presenting significant safety risks.
Reviewed by	Pharmacy Compounding Advisory Committee (PCAC)
Applies to	Compounding for patient use — not research-use-only supply

Placement is not permanent — the FDA can move substances between categories as new evidence is reviewed, which is exactly what the July 2026 meeting is part of. Regulatory review of compounding eligibility is a separate question from drug approval, and neither is the same as research-use-only sale.

042026 Timeline

Early 2026The regulatory status of multiple peptides used in compounding comes under renewed federal review.
Spring 2026Changes to the interim compounding lists take effect, prompting many researchers to seek documented, transparent research-use-only suppliers.
Jul 23–24 2026The FDA Pharmacy Compounding Advisory Committee is scheduled to review evidence on BPC-157, KPV, TB-500, MOTS-C, DSIP, Semax, and Epitalon.
OngoingEthos Bio monitors the landscape and maintains strict research-use-only framing, independent third-party testing, and per-lot documentation regardless of category placement.

05Where Ethos Bio Stands

Ethos Bio sells every compound strictly for laboratory research use only — not for compounding, human or veterinary use, diagnosis, or treatment. That has not changed and does not depend on any category decision. What we control, we hold to a high standard: independent five-point testing by MZ Biolabs, a batch-specific Certificate of Analysis on every order, and disciplined, compliant framing across the catalog. See how we test →

06FAQ

What is happening with peptide regulation in 2026?

The FDA is re-evaluating the regulatory status of several peptides considered for pharmacy compounding. Its Pharmacy Compounding Advisory Committee is scheduled to meet July 23–24, 2026 to review evidence on a set of peptides. Ethos Bio supplies these compounds strictly for laboratory research use only, a channel distinct from compounding for patient use.

Which peptides is the FDA reviewing in July 2026?

Per the FDA meeting notice: BPC-157, KPV, TB-500, and MOTS-C on July 23, 2026; DSIP, Semax, and Epitalon on July 24, 2026.

What is the difference between Category 1 and Category 2?

Category 1 substances are under evaluation, with the FDA generally applying enforcement discretion while review continues; Category 2 substances are those identified as potentially presenting significant safety risks. Placement can change as evidence is reviewed.

Does review mean these are approved or unapproved drugs?

No. Compounding-eligibility review is separate from drug approval. Ethos Bio does not market these as approved drugs; they are supplied as research-use-only reference materials for laboratory study.

How does this affect Ethos Bio customers?

Ethos Bio sells strictly for laboratory research use only — a distinct channel from pharmacy compounding. We maintain research-use-only framing, independent third-party testing, and documentation on every lot regardless of category decisions.

This page is an informational summary of publicly available regulatory activity and is not legal, medical, or compounding advice. Primary source: U.S. FDA Pharmacy Compounding Advisory Committee materials and Federal Register notices (docket FDA-2026-N-2979). For authoritative detail, consult FDA.gov.